Aurobindo Pharma has received final approval from the USFDA to manufacture and market Fenofibrate tablets which are used for the treatment of high level of cholesterol. The company will produce the drug in Tablets form of 48 mg and 145 mg. The product is expected to be launched in the first quarter of this fiscal. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product Tricor tablets of AbbVie Inc. According to IMS, the approved product has an estimated market size of $412 million for the twelve months ended March 2016. It may be noted, Fenofibrate Tablet is used for the treatment of high cholesterol level and triglyceride in the blood.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply